TCEANC2

Across TCGA pan-cancer cohorts, TCEANC2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of TCEANC2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where TCEANC2 RNA is repressed in tumor relative to normal tissue. In most cancer types TCEANC2 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, LIHC, and KICH are the cancer types where TCEANC2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TCEANC2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.725	<.001	10	view →
LIHC	Female	II,III,IV	+0.687	<.001	9	view →
KICH	Female	All	−0.865	<.001	8	view →
CHOL	Female	All	+1.673	<.001	5	view →
BLCA	Female	All	+0.500	.030	2	view →
STAD	All	II,III,IV	+0.386	.014	2	view →
KIRP	All	IV	+0.345	.024	2	view →
LUAD	Male	All	+0.231	.026	2	view →
BRCA	Female	All	−0.119	.027	2	view →
HNSC	Female	III,IV	+0.445	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

TCEANC2–THCA

Open the THCA breakdown →